Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease

General Information

Summary This study will evaluate the safety and efficacy of intracerebral transplantation of human embryonic stem cells-derived neural precursor cells in patients with Parkinson's Disease.
Description This study is a Phase I/II, open-label, non randomized clinical trial. The study will enroll 50 patients for cell injection, administering a single dose of neural precursor cells by stereotaxic intra-striatal injection.
Clinical trials phase Phases 1/2
Start date (estimated) 2017-05-01
End date (estimated) 2020-12-31
Clinical feature
Label Parkinson's disease
Link http://purl.obolibrary.org/obo/DOID_14330
Description A synucleinopathy that has_material_basis_in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.; Xref MGI. OMIM mapping confirmed by DO. [SN].
Publications

Administrative Information

NCT number NCT03119636
ICTRP weblink https://trialsearch.who.int/Trial2.aspx?TrialID=NCT03119636
Other study identifiers
Name ChineseASZQ-003
Source weblink https://clinicaltrials.gov/show/NCT03119636
Regulatory body approval
Name National Health Commission of the PRC;National medical products administration
Country
China
Approval number CMR-20161213-1001
Study sites
Sponsors Chinese Academy of Sciences
Collaborators

Cells

Source pluripotent stem cell lines
Which differentiated cell type is used
Label dopaminergic neuron
Link http://purl.obolibrary.org/obo/CL_0000700
Description A neuron that releases dopamine as a neurotransmitter.

Recruitment

Recruitment Status Unknown Status
Estimated number of participants 50
Contact institutions/departments